Y-27632 dihydrochloride: Precision ROCK1/2 Inhibition for Advanced Cellular Studies

Executive Summary: Y-27632 dihydrochloride is a potent and selective small-molecule inhibitor of Rho-associated protein kinases (ROCK1 and ROCK2), exhibiting an IC50 of 140 nM for ROCK1 and a Ki of 300 nM for ROCK2 in vitro (APExBIO). This compound shows over 200-fold selectivity against other kinases, enabling precise modulation of the Rho/ROCK signaling pathway (Pereira et al., 2025). Y-27632 disrupts Rho-mediated stress fiber formation, modulates cytokinesis, and enhances stem cell viability. Its solubility profile allows flexible use in DMSO, ethanol, and water, and it supports workflows in cancer and regenerative medicine research. APExBIO supplies Y-27632 dihydrochloride (SKU A3008) with validated protocols for reproducibility and scalability.

Biological Rationale

The Rho/ROCK signaling axis regulates actin cytoskeleton dynamics, cellular contractility, and cell cycle progression. Dysregulation of this pathway is implicated in tumor invasion, metastasis, and neurodevelopmental disorders (Pereira et al., 2025). RhoA activation recruits ROCK kinases, promoting phosphorylation of downstream effectors such as myosin light chain (MLC), LIM kinase, and cofilin. This cascade controls the assembly of actin stress fibers and focal adhesions, which are critical for cell shape, motility, and division. Inhibitors like Y-27632 dihydrochloride enable targeted disruption of these processes, facilitating mechanistic studies in cell biology, cancer, and stem cell research. Recent studies also highlight the utility of ROCK inhibition in dissecting epigenetic regulatory networks and enhancer-promoter interactions, as seen in models of Gabriele-de Vries syndrome (Pereira et al., 2025).

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a synthetic, cell-permeable pyridine derivative that competitively inhibits the ATP-binding site of ROCK1 and ROCK2 kinases. It displays an IC50 of approximately 140 nM for ROCK1 and a Ki of 300 nM for ROCK2 under standard in vitro kinase assay conditions (pH 7.4, 25°C, ATP 10 μM) (APExBIO). Selectivity profiling demonstrates over 200-fold lower activity toward PKC, cAMP-dependent protein kinase, MLCK, and PAK. Upon inhibition of ROCK, phosphorylation of MLC and LIM kinase is reduced, leading to the disassembly of actin stress fibers and decreased cellular contractility. In cellular models, Y-27632 arrests cells in G1/S transition and interferes with cytokinesis (America Peptides), providing a mechanistic basis for its anti-proliferative effects. These properties underpin its utility in cytoskeletal studies, stem cell maintenance, and cancer progression assays.

Evidence & Benchmarks

• Y-27632 dihydrochloride inhibits ROCK1 with an IC50 of 140 nM and ROCK2 with a Ki of 300 nM in biochemical assays (APExBIO).
• Demonstrates >200-fold selectivity for ROCK over PKC and MLCK, validated by kinase panel screening assays (Pereira et al., 2025).
• Reduces proliferation of prostatic smooth muscle cells in vitro in a concentration-dependent manner (1–10 μM, 48 h, DMEM, 37°C) (APExBIO).
• Suppresses tumor invasion and metastasis in mouse xenograft models by disrupting cytoskeletal dynamics (5–30 mg/kg, IP, 21 days) (America Peptides).
• Enhances survival and proliferation of human pluripotent stem cells post-dissociation (10 μM, 24 h) (L3400).
• Solubility: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water at 25°C (APExBIO).
• Stock solutions are stable at -20°C for several months in desiccated conditions (APExBIO).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely applied in cell proliferation assays, cytoskeletal studies, stem cell viability and expansion, and cancer research. Its ability to selectively inhibit ROCK1/2 is leveraged to dissect Rho/ROCK pathway contributions to cell migration, invasion, and cytokinesis. By modulating actin dynamics, it improves survival of dissociated embryonic and induced pluripotent stem cells, facilitating genetic manipulations and clonal expansion (L3400). In cancer models, Y-27632 suppresses invasion and metastasis by interfering with actomyosin contractility and focal adhesion turnover (America Peptides). Optimizing Cell Assays with Y-27632 dihydrochloride provides scenario-driven protocols for enhancing reproducibility, whereas this article extends the focus by integrating recent in vivo evidence and benchmarking selectivity. Y-27632 Dihydrochloride: Precision ROCK Inhibition for Epigenetic Studies details the link between Rho/ROCK signaling and epigenetic regulation; here, the mechanistic impact on cytoskeletal and metastatic processes is clarified. Y-27632 Dihydrochloride: Unleashing the Power of Selective ROCK Inhibition discusses translational potential in 3D cancer models; this dossier further benchmarks compound selectivity and workflow integration.

Common Pitfalls or Misconceptions

• Y-27632 dihydrochloride is not effective against non-ROCK kinases at experimental concentrations (≤10 μM).
• Long-term storage of solutions (especially in aqueous media) can reduce compound potency due to hydrolysis; prepare fresh aliquots when possible.
• Does not reverse pre-existing actin stress fiber formation if ROCK signaling has adapted or is compensated by alternative pathways.
• Not suitable for in vivo use in humans; limited to preclinical animal studies and in vitro/ex vivo applications.
• Overuse in stem cell cultures may mask underlying cellular heterogeneity or alter differentiation potential.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid by APExBIO (SKU A3008), recommended to be stored desiccated at 4°C or lower. Dissolve to ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water. To enhance solubility, warm at 37°C or use an ultrasonic bath. Prepare working solutions fresh; stock aliquots are stable for several months at -20°C. For cell-based assays, final concentrations typically range from 1 μM to 30 μM. In stem cell applications, 10 μM for 24 hours post-dissociation is standard. For in vivo mouse models, doses of 5–30 mg/kg (IP) have shown efficacy in reducing tumor invasiveness. Avoid repeated freeze-thaw cycles to maintain potency. Full details and validated protocols are available on the Y-27632 dihydrochloride product page.

Conclusion & Outlook

Y-27632 dihydrochloride is a rigorously validated, selective ROCK1/2 inhibitor. It enables targeted manipulation of Rho/ROCK signaling, supporting mechanistic studies in cell biology, stem cell research, and cancer models. Its proven selectivity, solubility, and workflow flexibility make it a gold-standard tool for dissecting cytoskeletal and proliferative responses. Future applications include advanced organoid models, enhanceropathy research, and translation to precision cell therapy protocols. For sourcing, validated protocols, and technical support, APExBIO remains a primary provider of Y-27632 dihydrochloride (A3008).